

Allantodapsone is a Pan-Inhibitor of Staphylococcus aureus Adhesion to Fibrinogen, Loricrin, and Cytokeratin 10

Prencipe, Filippo; Alsibae, Aishah; Khaddem, Zainab; Norton, Padraig; Towell, Aisling M; Ali, Afnan F M; Reid, Gerard; Fleury, Orla M; Foster, Timothy J; Geoghegan, Joan A; Rozas, Isabel; Brennan, Marian P

DOI:

[10.1128/spectrum.01175-21](https://doi.org/10.1128/spectrum.01175-21)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Prencipe, F, Alsibae, A, Khaddem, Z, Norton, P, Towell, AM, Ali, AFM, Reid, G, Fleury, OM, Foster, TJ, Geoghegan, JA, Rozas, I & Brennan, MP 2022, 'Allantodapsone is a Pan-Inhibitor of Staphylococcus aureus Adhesion to Fibrinogen, Loricrin, and Cytokeratin 10', *Microbiology spectrum*, vol. 10, no. 3, e0117521. <https://doi.org/10.1128/spectrum.01175-21>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



Allantodapsonone is a Pan-Inhibitor of *Staphylococcus aureus* Adhesion to Fibrinogen, Loricrin, and Cytokeratin 10

Filippo Prencepe,^a  Aishah Alsibae,^b Zainab Khaddem,^b Pdraig Norton,^b  Aisling M. Towell,^c Afnan F. M. Ali,^b Gerard Reid,^a  Orla M. Fleury,^c  Timothy J. Foster,^c  Joan A. Geoghegan,^{c,d}  Isabel Rozas,^a  Marian P. Brennan^b

^aSchool of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

^bSchool of Pharmacy and Biomedical Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland

^cDepartment of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, Dublin, Ireland

^dInstitute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham, United Kingdom

Filippo Prencepe and Aishah Alsibae contributed equally to this article. Author order was determined on the basis of seniority.

ABSTRACT *Staphylococcus aureus* infections have become a major challenge in health care due to increasing antibiotic resistance. We aimed to design small molecule inhibitors of *S. aureus* surface proteins to be developed as colonization inhibitors. We identified allantodapsonone in an initial screen searching for inhibitors of clumping factors A and B (ClfA and ClfB). We used microbial adhesion assays to investigate the effect of allantodapsonone on extracellular matrix protein interactions. Allantodapsonone inhibited *S. aureus* Newman adhesion to fibrinogen with an IC₅₀ of 21.3 μM (95% CI 4.5–102 μM), minimum adhesion inhibitory concentration (MAIC) of 100 μM (40.2 μg/mL). Additionally, allantodapsonone inhibited adhesion of *Lactococcus lactis* strains exogenously expressing the clumping factors to fibrinogen (*L. lactis* ClfA, IC₅₀ of 3.8 μM [95% CI 1.0–14.3 μM], MAIC 10 μM, 4.0 μg/mL; and *L. lactis* ClfB, IC₅₀ of 11.0 μM [95% CI 0.9–13.6 μM], MAIC 33 μM, 13.3 μg/mL), indicating specific inhibition. Furthermore, the dapsonone and alloxan fragments of allantodapsonone did not have any inhibitory effect. Adhesion of *S. aureus* Newman to L2v loricrin is dependent on the expression of ClfB. Allantodapsonone caused a dose dependent inhibition of *S. aureus* adhesion to the L2v loricrin fragment, with full inhibition at 40 μM (OD₆₀₀ 0.11 ± 0.01). Furthermore, recombinant ClfB protein binding to L2v loricrin was inhibited by allantodapsonone (*P* < 0.0001). Allantodapsonone also demonstrated dose dependent inhibition of *S. aureus* Newman adhesion to cytokeratin 10 (CK10). Allantodapsonone is the first small molecule inhibitor of the *S. aureus* clumping factors with potential for development as a colonization inhibitor.

IMPORTANCE *S. aureus* colonization of the nares and the skin provide a reservoir of bacteria that can be transferred to wounds that can ultimately result in systemic infections. Antibiotic resistance can make these infections difficult to treat with significant associated morbidity and mortality. We have identified and characterized a first-in-class small molecule inhibitor of the *S. aureus* clumping factors A and B, which has the potential to be developed further as a colonization inhibitor.

KEYWORDS ClfA, ClfB, MRSA, MSSA, *Staphylococcus aureus*, allantodapsonone, atopic dermatitis, clumping factors, cytokeratin 10, loricrin, nasal colonization, wound infection

Antibiotic resistance is one of the greatest challenges to health care, and *S. aureus* infections are increasingly becoming a problem in the clinic. *S. aureus* is responsible for serious infections such as infective endocarditis, pneumonia, infections of joints, indwelling devices, and sepsis. It is also a major cause for abscesses, impetigo, and surgical wound infections, which often lead to severe complications for patients. Methicillin resistant *S. aureus* (MRSA)

Editor Adriana E. Rosato, Riverside University Health System, Medical Center—University of California

Copyright © 2022 Prencepe et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Marian P. Brennan, mbrennan@rcsi.com.

The authors declare no conflict of interest.

Received 28 October 2021

Accepted 17 April 2022

is now widespread both in the community and in patient populations. Even though this can be treated relatively successfully with vancomycin or daptomycin, mortality rates associated with infection are still extremely high. Susceptibility to vancomycin has also decreased in some strains, with a rise in vancomycin intermediate *S. aureus* (VISA) strains. Although daptomycin can be used for vancomycin failures, daptomycin resistance has also developed in some *S. aureus* strains (1). Increasing antibiotic resistance and multidrug resistant strains provide a strong case for the development of novel treatments for *S. aureus* infection targeting novel mechanisms of action. Nasal colonization with MRSA is a source of transmission within the hospital setting. The antibiotic mupirocin is used for nasal decolonization of MRSA; however, mupirocin resistant strains have emerged.

The microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) are a well characterized set of surface proteins that are involved in host–pathogen interactions including wound and nasal colonization, as well as interactions with platelets. The ubiquitous clumping factors (ClfA and ClfB) have been identified as virulence factors present in both methicillin sensitive and methicillin resistant strains and thus are considered essential for *S. aureus* colonization and infection (2). These clumping factors are compelling drug targets because of their surface expression and their ability to interact with multiple ligands. They can adhere to exposed fibrinogen in wounds when the extracellular matrix is exposed. Furthermore, they clump bacteria together in the presence of soluble fibrinogen and can lead to platelet activation and aggregation (3, 4), which is responsible for the thrombotic complications associated with systemic infections. ClfA binds to the C-terminus of the γ -chain of fibrinogen (5). ClfB binds to the C-terminus of the α -chain of fibrinogen (6, 7), as well as to cytokeratin 10 (CK10) (8, 9), cytokeratin 8 (10), and loricrin (11, 12). The interaction with loricrin has been shown to be key in nasal colonization (11). While these two clumping factors have different peptide ligands, they have extremely similar three-dimensional structures in their ligand binding domains, which have a groove that runs along between the N2 and N3 subunits of the A-domain. Co-crystal structures of ClfA complexed with fibrinogen (13) and ClfB with fibrinogen, CK10, and dermokine have been solved (14, 15) allowing for detailed characterization of these interactions.

The objective of this project was to employ *in silico* methods to develop molecules that could potentially fit into the ligand binding trenches of both ClfA and ClfB. Such a molecule might be the prototype of a pan-inhibitor of bacterial adhesion for inhibiting colonization of the nares and surgical wounds. Allantodapsone was identified and its ability to inhibit bacterial adhesion to immobilized ligands was tested. The activity of the molecule was explored using substructure fragments and synthesized derivatives.

Here we present a novel inhibitor of *S. aureus* adhesion, allantodapsone, that inhibits adhesion to fibrinogen, loricrin, and cytokeratin 10. This inhibitor targets bacterial adhesion through inhibition of the ligand binding activity of ClfA and ClfB. This is the first reported small molecule inhibitor for any MSCRAMM and thus has the potential to be developed as an inhibitor of nasal or skin colonization or for the treatment of wound infections.

RESULTS

Inhibition of *S. aureus* adhesion to ligands by allantodapsone. *In vitro* screening of compounds from the ZINC database (16) led to the initial identification of allantodapsone as an inhibitor of *S. aureus* Newman adhesion to fibrinogen (Fig. 1). The virulence factors targeted in this study are expressed in both MSSA and MRSA strains (17). *S. aureus* Newman is a clinically derived strain, with well characterized expression of ClfA and ClfB (18, 19). The ability of allantodapsone to inhibit *S. aureus* Newman growing to stationary phase was initially tested. Under these conditions, ClfA is the dominant MSCRAMM on the bacterial surface and there is little or no ClfB expression (6). Allantodapsone caused a dose dependent inhibition of adhesion of *S. aureus* to immobilized fibrinogen with an IC_{50} of 21.3 μ M (95% CI 4.5–102 μ M), minimum adhesion inhibitory concentration (MAIC) of 100 μ M (40.2 μ g/mL) (Fig. 1A). *L. lactis* has been employed as a surrogate Gram-positive bacterial host to express individual MSCRAMMs in isolation (19). ClfA and ClfB can be expressed individually on the surface of this surrogate host.




FIG 1 Allantodapson inhibits *S. aureus* Newman adhesion to fibrinogen. Dose response curves for *S. aureus* Newman (A), *L. lactis* ClfA (B), and *L. lactis* ClfB (C) adhesion to fibrinogen. Fibrinogen was used to coat plates at 4°C overnight at 10 $\mu\text{g}/\text{mL}$. Wells were washed with PBS and blocked with 1% BSA. Washed bacteria (OD_{600} of 1) were mixed with the relevant concentration of allantodapson or vehicle control (DMSO) for 5 min, and added to the wells, incubating for 2 h at 37°C. Adherent cells were washed, fixed, and stained with crystal violet, and wells further washed. The dye was dissolved in acetic acid and the absorbance measured at 570 nm. IC_{50} values were generated using GraphPad Prism 9.0 GraphPad software, San Diego, CA. Data are representative of three experiments with error presented as SEM.

Both ClfA and ClfB have been shown to be expressed on the surface of *L. lactis* using this expression system and functionally able to support adhesion to fibrinogen where the *L. lactis* wild-type host strain does not (19). *L. lactis* expressing ClfA and *L. lactis* expressing ClfB display similar adhesion levels to *S. aureus* Newman and *S. aureus* SH1000 strains. Comparative adhesion to fibrinogen for strains used in this study is presented in Fig. S1 in the supplemental material. Allantodapson inhibited adhesion of *L. lactis* ClfA to fibrinogen with an IC_{50} of 3.8 μM (95% CI 1.0–14.3 μM ; MAIC 10 μM ; 4.0 $\mu\text{g}/\text{mL}$) (Fig. 1B) and *L. lactis* ClfB adhesion to fibrinogen with an IC_{50} of 11.0 μM (95% CI 8.9–13.6 μM ; MAIC 33 μM ; 13.3 $\mu\text{g}/\text{mL}$) (Fig. 1C). Allantodapson also inhibited adhesion to fibrinogen by Newman grown to the exponential phase (Fig. 2). *S. aureus* strain SH1000 produces two additional fibrinogen binding proteins not expressed by Newman, fibronectin binding protein A (FnBPA) and FnBPB. Adhesion of strain SH1000 to fibrinogen in both the stationary and exponential growth phases was inhibited by allantodapson (Fig. 2). Comparative results for all strains is presented in Table 1. Further assays demonstrated that allantodapson did not inhibit adhesion of *S. aureus* SH1000 to fibronectin (Fig. S2).

Investigating substructures of allantodapson. Allantodapson is a composite molecule formed from dapson and alloxan substructures. The individual components were tested for inhibition of adhesion of *S. aureus* Newman and strain SH1000 growing to exponential phase and to stationary phase. Neither dapson nor alloxan had any inhibitory activity at the concentration of allantodapson that reduced adhesion of *S. aureus* strains to fibrinogen (Fig. 2).

Investigation of effects on bacterial growth. Alloxan is known to have toxic effects (20, 21); therefore, we tested allantodapson to assess if it had any effects on bacterial growth. In order to determine if allantodapson had growth inhibitory properties, *S. aureus* Newman cells were diluted into fresh broth containing different concentrations of allantodapson and incubated to allow growth to occur (Fig. 3). Even at the highest concentration




FIG 2 Allantodapson inhibits *S. aureus* adhesion to fibrinogen. (A) *S. aureus* Newman stationary phase and (B) exponential phase. (C) *S. aureus* SH1000 stationary phase and (D) exponential phase bacteria. Fibrinogen was used to coat plates at 4°C overnight at 10 $\mu\text{g}/\text{mL}$. Wells were washed with PBS and blocked with 1% BSA. Washed bacteria (OD₆₀₀ of 1) were mixed with the relevant concentration of allantodapson or vehicle control for 5 min, and added to the wells, incubating for 2 h at 37°C. Adherent cells were washed, fixed, and stained with crystal violet, and wells further washed. The dye was dissolved in acetic acid and the absorbance measured at 570 nm. Compounds were screened at a concentration of 70 μM and compared to their vehicle control. Statistical analysis was carried out using repeated measures ANOVA followed by multiple comparisons Dunnett's tests using GraphPad PRISM. **, $P \leq 0.01$; ***, $P \leq 0.001$; ****, $P \leq 0.0001$ ($n = 3$).

of allantodapson tested (100 μM), there was no inhibition of bacterial growth compared to the vehicle control. In contrast, the antibiotic ampicillin had a pronounced inhibitory effect on growth. The MIC₉₀ in this assay for *S. aureus* Newman was 0.03 μM (0.01 $\mu\text{g}/\text{mL}$). The MIC₉₀ for ampicillin is reported for *S. aureus* isolates in the range of 0.015–4 $\mu\text{g}/\text{mL}$, using the microdilution method in MSSA isolates (22, 23). Dapsone also inhibited growth with an MIC₉₀ of 0.3 μM (0.1 $\mu\text{g}/\text{mL}$). An MIC₉₀ for dapson was previously determined in MSSA strains as 128 $\mu\text{g}/\text{mL}$ (32–256 $\mu\text{g}/\text{mL}$) (24). A preliminary toxicity test was performed in human cells where no toxic effects were seen when allantodapson was tested at a 100 μM concentration (Fig. S3).

Inhibition of adhesion to lorricrin and cytokeratin 10. The ability of *S. aureus* Newman to adhere to lorricrin and cytokeratin 10 is crucial for colonization of the nares of carriers and the

TABLE 1 Summary of IC₅₀ values for inhibition of adhesion to fibrinogen^a

Bacteria	IC ₅₀ (μM)	95% confidence interval (μM)
<i>S. aureus</i> Newman (exponential phase)	32.8	21.3–44.9
<i>S. aureus</i> Newman (stationary phase)	21.3	4.5–102
<i>S. aureus</i> SH1000 (exponential phase)	15.6	10.6–21.0
<i>S. aureus</i> SH1000 (stationary phase)	7.6	4.8–10.0
<i>L. lactis</i> ClfA	3.8	1.0–14.3
<i>L. lactis</i> ClfB	11.0	8.9–13.6

^aIC₅₀ values were generated using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA).




FIG 3 Allantodapson does not inhibit bacterial growth. *S. aureus* was grown in BHI broth shaking overnight at 37°C in the presence of a range of concentrations of allantodapson, dapsone, or ampicillin as control. Absorbance was measured the following day at 570 nm. Data have been normalized to the relevant vehicle control (1% DMSO for allantodapson and dapsone and water for ampicillin). These data represent three separate experiments. Error bars represent SEM.

skin of eczema patients. Adhesion is mediated exclusively by ClfB (11). The *in vitro* expressed recombinant GST-L2v protein contains a high affinity binding site for ClfB from human loricrin.

Figure 4A demonstrates that allantodapson caused a dose dependent inhibition of *S. aureus* adhesion to GST-L2v (the high affinity ClfB binding site within loricrin), with full




FIG 4 Allantodapson inhibits *S. aureus* adhesion to loricrin and cytokeatin 10. Dose-response curve for adhesion of *S. aureus* Newman to GST-L2v loricrin (A) and CK10 (C). (B) Inhibition of recombinant ClfB N2N3 binding to immobilized GST-L2v loricrin by allantodapson. (D) Inhibition of *S. aureus* Newman adhesion to GST-L2v loricrin by allantodapson derivatives. Purified GST-L2v or CK10 were used to coat plates at 4°C overnight. Wells were washed with PBS and blocked with 1% BSA. Washed bacteria (OD₆₀₀ of 1) were mixed with allantodapson or vehicle control before being added to the wells and incubated for 2 h at 37°C. Adherent cells were washed, fixed, and stained with crystal violet, and wells further washed. The dye was dissolved in acetic acid, and the absorbance measured at 570 nm. GST-L2v was used at 20 μM in A and D. CK10 was used at 10 nM. Test compounds were incubated with bacteria at 80 μM and normalized to the DMSO vehicle control in D. For data presented in B, recombinant ClfB was incubated with allantodapson (100 μM) or DMSO (1%) for 30 min prior to being added to wells coated with recombinant GST-L2v loricrin. Bound ClfB was detected using peroxidase-conjugated anti-His monoclonal antibody in an ELISA. The graphs shown are representative of three independent experiments. Statistics were carried out using one-way ANOVA followed by the Dunnett's posttest using GraphPad Prism version 9.0.













FIG 5 Predicted binding interactions for allantodapsone and compound 11 with ClfA and ClfB. Panel A represents predicted ligand interactions with ClfA. The co-crystal structure (PDB 2VR3) is presented with the fibrinopeptide depicted as a yellow ribbon orientating the binding site. The carbons of allantodapsone are colored green, and the carbons of compound 11 are colored pink. Oxygen is colored red, nitrogen-blue, chlorine-dark green, and fluorine-bright green. The final column presents an overlay of the two compounds. Panel B represents ClfB structures. The ClfB co-crystal structure peptide ligands are predicted to bind to the same binding site in the groove between the N2 and N3 of the A domain. Superposition of ClfB crystal structures with peptide ligands was performed using MOE (Chemical Computing Group, Montreal). ClfB and the peptide ligands are presented as ribbon structures. ClfB is presented with the N-terminus in purple and the C-term in cyan. The dermokinase peptide is presented in yellow, CK10 peptide in blue, and the fibrinogen alpha chain peptide in red. The structures used for this overlay are PDB 4F20, 4F1Z, and 4F27. Magnesium ions are depicted as space-fill and colored pink. The zoomed-in panels represent the predicted binding poses for allantodapsone and compound 11 to ClfB (PDB 4F20). The small molecules are depicted as space-fill with hydrogen atoms hidden. The final column represents the overlay of the two best docking poses for allantodapsone and compound 11.






inhibition at 40 μ M (OD₆₀₀ 0.11 \pm 0.01). Furthermore, recombinant ClfB binding to L2v loricrin was inhibited by allantodapsone ($P < 0.0001$) (Fig. 4B). In this experiment, the N2 and N3 subunits of the ligand binding A-domain of ClfB (ClfB N2N3) was used,

TABLE 2 Summary of chemical derivatives synthesized and tested with docking results for ClfA and ClfB^a

Name	Structure	ClfA docking score (kcal/mol)	ClfB docking score (kcal/mol)
Allantodapsone		-8.05	-7.15
1		-7.22	-7.13
2		-7.80	-7.72
3		-9.32	-8.43
4		-8.93	-7.29
5		-7.76	-6.27
6		-9.77	-8.72
7		-7.01	-6.41
8		-7.13	-6.33

(Continued on next page)

TABLE 2 (Continued)

Name	Structure	ClfA docking score (kcal/mol)	ClfB docking score (kcal/mol)
9		-6.95	-6.30
10		-7.03	-6.63
11		-7.95	-7.53
12		-6.96	-6.25
13		-8.14	-7.34

^aScores obtained from docking all the compounds studied into ClfA and ClfB are presented. Proteins were prepared using Proteinate3D and docking performed using the dock function in MOE (CCG, Montreal, Canada). PDB structures 2VR3 and 4F20 were used for ClfA and ClfB docking, respectively.

demonstrating specificity for this domain on ClfB. Allantodapson also demonstrated dose dependent inhibition of *S. aureus* adhesion to CK10 (Fig. 4C).

Structural analysis and derivative design. As individual fragments of allantodapson (dapson, alloxan, and violuric acid) did not show any activity, we sought to better understand the allantodapson structure–activity relationship and to improve its biological activity. Thus, a series of novel allantodapson related compounds were designed and their interaction with ClfA and ClfB computationally analyzed by docking studies using the crystallized structure of ClfA and ClfB as templates (PDB: 2VR3 and 4F20). The fibrinogen γ -chain peptide has been co-crystallized with ClfA binding between the N2 and N3 domains as depicted in Fig. 5A (13). CK10, dermokine, and α -chain fibrinogen peptides have been cocrystallized with ClfB (13, 15), demonstrating that they occupy the similar peptide binding groove between the N2 and N3 domains of the A domain of ClfB. An overlay of the three structures is presented in Fig. 5B, demonstrating that these peptides share the same binding site. Our docking studies predicted that allantodapson binds into the same peptide binding groove in both ClfA and ClfB (Fig. 5), suggesting that it would be able to directly compete with the natural peptide ligands.

In terms of the novel derivatives proposed, structural modifications considered to elucidate and improve its interaction with the target involved (i) changing the sulfur atom oxidation state from sulfone to sulfide to investigate the role of the two sulfoxide groups upon binding to the target (compounds 1–5, 7–8), (ii) modifying the spacer between the dapson portion and the alloxan-like moiety by increasing the carbon chain length (compounds 1–3), (iii) connecting flexible chains to the dapson core by means a urea/thiourea linker (6–8), as well as (iv) reducing the flexibility of the system introducing an amide group or introducing a spiro function (compounds 2–5) (see structures in Table 2). Additionally, a number of compounds with a similar diatomic core as allantodapson were selected from Rozas' library; these compounds contain different bis-guanidinium diaryl derivatives 3,4'- or 4,4'-

substituted and with additional aromatic systems in one of the guanidinium groups (compounds 9–13; see structures in Table 2).

Molecular docking was used to explore the predicted structure activity relationships for ClfA and ClfB, and the results are presented in Table 2. All compounds showed scores similar or even better than those of allantodapson, and accordingly they were deemed to be potential ClfA and ClfB inhibitors and their synthesis was attempted.

These new compounds (1–7), together with those selected from Rozas' library (8–13, 25), were screened for activity using adhesion of *S. aureus* Newman to L2v loricrin at 80 μM (Fig. 4D). Only compound 11 demonstrated activity (61.3% \pm 7% adhesion); however, this was not as potent as allantodapson, which has an IC_{50} of 9.87 μM in this assay and full inhibition at 40 μM (16.1 $\mu\text{g}/\text{mL}$) (Fig. 4A). Compounds 6–8 were also screened at 40 μM and showed no significant inhibition (data not shown). Compound 11 has been previously shown to exert toxicity in human cancer cells such as HL-60, HeLa, and MCF-7 in the micromolar concentration range (IC_{50} values between 11 and 28 μM) (26), suggesting that this compound would also have other off-target effects.

To understand these outcomes, we analyzed the docking results obtained with compound 11 and allantodapson with ClfA and ClfB. The best pose of allantodapson bound to ClfA predicts the formation of a specific hydrogen bond with the side chain of Asn⁵²⁵ and with the peptide backbone of Asn⁵³⁰ and Ile³⁸⁴, while the ring structure of the dapson substructure has a predicted arene-H interaction with Val⁵²⁷ (Fig. 5A). While compound 11 binds to the same general region (overlay panel), it is predicted to interact with different amino acids. The guanidinium group of compound 11 is predicted to form a salt bridge with the Glu⁵²⁶; additionally, it is also predicted to have a backbone interaction with Ala⁵²⁸, and an arene-H interaction with Asn⁵²⁵.

Glu⁵²⁶ and Val⁵²⁷ have been shown to be important for ClfA adhesion to fibrinogen (27), Tyr³³⁸ has also been demonstrated to be crucial for fibrinogen binding (3, 28). Both compound 11 and allantodapson top poses are near to Tyr³³⁸, suggesting that they would block this interaction.

In the case of docking to ClfB, predicted hydrogen bonding occurs through Asn²⁶⁸, Tyr²⁷³, and Glu⁵²⁵, with a pi-pi interaction predicted with Phe³²⁸ for allantodapson. Phe³²⁸ was shown to be an important residue in the interaction between ClfB with CK10 and dermokin (15).

Compound 11 is predicted to form hydrogen bonds between the guanidinium group and Gly²³⁷ and with Gly⁵³¹, as well as an arene-H interaction with Arg⁵²⁹. The top docking poses for both allantodapson and compound 11 are near to Ser²³⁶, which has been shown to be important for binding of fibrinogen dermokin and CK10 (15). Both compounds are predicted to completely block the peptide binding site and therefore are foreseen to inhibit interactions with all peptide ligands binding to the binding trench.

Based on the experimental data, allantodapson is the most promising inhibitor of *S. aureus* adhesion identified in this work. As ClfA and ClfB are also important MSCRAMM's involved in the activation of platelets, important in the pathogenesis of sepsis, we sought to investigate if allantodapson had any effect on bacterial-induced platelet activation. Inhibition of this interaction therefore could be beneficial to patients. We demonstrated that allantodapson did not inhibit platelet aggregation induced by *S. aureus* Newman (Fig. S4A). We further investigated whether allantodapson could inhibit soluble fibrinogen binding using the agglutination assay. *S. aureus* Newman was washed and resuspended in fibrinogen in order to investigate the clumping factors without the presence of coagulase that is secreted. Allantodapson did not inhibit clumping of bacteria in a fibrinogen clumping assay (Fig. S4B). These results together suggest that allantodapson does not inhibit the interaction of soluble fibrinogen with ClfB and that the inhibition demonstrated is limited to immobilized fibrinogen.

DISCUSSION

Allantodapson was originally identified as an inhibitor of protein arginine methyltransferase 1 (PRMT1) from virtual high throughput screening (29). We have shown that allantodapson inhibits adhesion of ClfB to fibrinogen, CK10, and L2v loricrin, making it an ideal

TABLE 3 Summary of bacterial strains utilized in this study

Bacterial strain	Genotype or description	Reference
<i>L. lactis</i> control	Strain MG1363	Gasson et al. (38)
<i>L. lactis</i> ClfA	Strain MG1363 expressing plasmid pKS80 carrying the <i>clfA</i> gene	O'Brien et al. (19)
<i>L. lactis</i> ClfB	Strain MG1363 expressing plasmid pKS80 carrying the <i>clfB</i> gene	O'Brien et al. (19)
<i>S. aureus</i> Newman	NCTC8178, clinical isolate	Duthie et al. (18)
<i>S. aureus</i> SH1000	Derivative of strain 8325-4, <i>rsbU</i> ⁺	Horsburgh et al. (36)

candidate for development as an inhibitor for nasal colonization or for atopic dermatitis. It further inhibits both ClfA and ClfB adhesion to fibrinogen, indicating that it may also be useful for inhibition of wound colonization. It inhibits adhesion of both *S. aureus* Newman and SH1000 to fibrinogen. *S. aureus* SH1000 expresses the fibronectin binding proteins FnBPA and FnBPB that bind to fibronectin as well as fibrinogen. Thus, our results suggest that allantodapson is an inhibitor of the clumping factors A and B as well as the fibronectin binding proteins FnBPA and FnBPB binding to fibrinogen. The lack of inhibition of *S. aureus* SH1000 to fibronectin suggests that there is some specificity. The fibronectin binding site is distinct from the fibrinogen binding site on the fibronectin binding proteins, and therefore this is not unexpected, as FnBPA, FnBPB, and ClfA also share the same ligand binding sequence in fibrinogen. ClfB and FnBPB have been recently shown to interact with corneodesmosin on the surface of deformed corneocytes in inflamed eczema skin (30). Therefore, further work to investigate the effect of allantodapson on this interaction is required.

Unexpectedly, allantodapson did not inhibit platelet aggregation or clumping of *S. aureus* in a solution of fibrinogen, suggesting that it does not inhibit the interaction of *S. aureus* with soluble fibrinogen. The reasons for this are not clear, but the high affinity binding of ClfA to fibrinogen involves both docking of the fibrinogen γ -chain in the hydrophobic binding trench (11, 31) and another interaction at a second distinct site at the top of the N3 subdomain. Based on our predicted docking site, allantodapson is unlikely to interfere with this second site interaction on the N3 subdomain. Ganesh et al. (32) found that the reverse was true, with a monoclonal antibody recognizing an epitope overlapping with the second fibrinogen binding site on N3, inhibiting binding to soluble fibrinogen to a greater extent than immobilized fibrinogen. They showed that the antibody did not inhibit binding of the fibrinogen γ -chain to the hydrophobic trench where allantodapson is predicted to bind.

While the allantodapson molecule itself does not appear to have toxic side effects, there is some concern as to the potential toxicity of the alloxan and dapson fragments. We therefore sought to alter these components. While complete loss of activity was seen in most compounds screened, compound 11 maintained some activity providing us with a possible new scaffold for development. Docking studies suggest that the overall position is similar for compound 11 and allantodapson, but specific interactions are different. While compound 11 had slightly reduced activity compared to allantodapson, it is possible that extending the molecule further along the binding groove may increase the ligand interactions with the protein and therefore improve activity. Replacement of the 4-chloro-3-(trifluoromethyl)benzamide group with a phenylguanidinium group (i.e., compound 10) resulted in a loss of activity for this new scaffold, suggesting that this hydrophobic group is important for specificity. In the modeling of compound 11, this group was predicted to form a hydrogen bond in the ClfB structure.

Here we present novel inhibitors of the MSCRAMMs, ClfA, and ClfB. Identification of novel inhibitors of the clumping factors is enticing as development of resistance to this class of molecules would be less likely, as any loss of binding to the compound would also lead to loss of ability to colonize the host due to disruption of the binding interaction with the natural ligand. This ligand binding region between the N2 and N3 subdomains has been shown to be completely conserved in ClfA and ClfB in both MSSA and MRSA strains (33). Therefore, a major advantage of adhesion blockers, compared to antibiotics, is that there is no selective advantage for development of resistance. The surface-located clumping factors are expressed ubiquitously in clinical strains including antibiotic resistance strains (2, 17). Therefore, while our experiments were performed using methicillin sensitive strains,

and *L. lactis* expressing the clumping factors, activity against all *S. aureus* strains expressing the clumping factors is a reasonable expectation. These surface proteins are crucial for host colonization. Furthermore, as this is a new target that has not been previously exploited by antibiotics, there are no current antibiotic resistance mechanisms to similar drugs.

Conclusion. Allantodapson inhibits *S. aureus* adhesion to fibrinogen and the ClfB ligands loricrin and cytokeratin 10. Loricrin binding to ClfB has been implicated as the primary mechanism that *S. aureus* uses to colonize the nares. ClfB also facilitates adherence of *S. aureus* to corneocytes in the stratum corneum to initiate skin colonization (31). Allantodapson therefore has potential for development as a novel therapeutic for the prevention of skin colonization in atopic dermatitis, wound colonization, and nasal colonization.

The *in vitro* work presented here demonstrates that it is possible to inhibit the interaction between the MSCRAMM's ClfA, ClfB, and their ligands cytokeratin 10, loricrin and fibrinogen. Allantodapson has potential for development as a colonization inhibitor; however, further testing using clinically relevant strains and *in vivo* models is required.

MATERIALS AND METHODS

Molecular modeling. ClfB structures were downloaded from the Protein Data Bank (34). The structures for ClfB, PDB ID 4F20, 4F1Z and 4F27, were used (15). ClfB structures and their ligands were superposed using the align/superpose function in the Molecular Operating Environment (Chemical Computing Group, Montreal, Canada). All ligands studied were prepared for docking using the “wash” function and all tautomers enumerated. CCPDB structures, 4F20 (ClfB) (15) and 2VR3 (ClfA) (13) were used as the targets and prepared for docking using the protonate 3D function with default parameters. The peptide ligand was used to define the binding site for docking using macromolecule residues within 4.5 Å of the peptide ligand. Docking was performed using the Triangle Matcher function for placement and London delta G scoring, storing 30 poses. Rigid receptor was used for refinement and GBVI/WSA delta G scoring for the final poses.

Chemistry. General conditions: All commercial chemicals were obtained from either Sigma-Aldrich or Fluka and used without further purification. Deuterated solvents for NMR spectroscopy use were purchased from Apollo. Column chromatography was performed using Sigma-Aldrich silica gel 100–200 mesh. Solvents for synthesis purposes were used at GPR grade. Analytical TLC was performed using either Merck Kieselgel 60 F254 silica gel plates or Polygram Alox N/UV254 aluminum oxide plates. Visualization was by UV light (254 nm). NMR spectra were recorded on Bruker DPX-400 Avance spectrometers, operating at 400.13 and 600.1 MHz for ¹H NMR, 100.6 and 150.9 MHz for ¹³C NMR. Shifts are referenced to the internal solvent signals.⁽¹⁾ NMR data were processed using Bruker TOPSPIN software. HRMS spectra were measured on a Micromass LCT electrospray TOF instrument with a WATERS 2690 autosampler and methanol/acetonitrile as carrier solvent. Melting points were determined using a Stuart SP10 melting point apparatus and are uncorrected. Infrared spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer equipped with a Universal ATR sampling accessory. HPLC purity analysis was carried out using a Varian ProStar system equipped with a Varian Prostar 335 diode array detector and a manual injector (20 μL). For purity assessment, UV detection was performed at 254 nm and peak purity was confirmed using a purity channel. The stationary phase consisted of an ACE 5 C18-AR column (150 × 4.6 mm), and the mobile phase used the following gradient system, eluting at 1 mL/min: aqueous formate buffer (30 mM, pH 3.0) for 10 min, linear ramp to 85% methanol buffered with the same system over 25 min, hold at 85% buffered methanol for 10 min. Minimum requirement for purity was set at 95.0%. Allantodapson was provided as a kind gift from the National Cancer Institute (Bethesda, USA). Alloxan, violuric acid, and dapson were purchased from Sigma-Aldrich, United Kingdom. Details of the preparation and characterization of all compounds studied are presented in the Supplemental Material.

Microbiology. (i) Bacterial strains. Strains used in this study are listed in Table 3. *S. aureus* strain Newman NCTC8178 was isolated from a patient suffering from osteomyelitis (18). It has been widely used to study *S. aureus* surface proteins and their roles in pathogenesis (19, 35). *S. aureus* strain SH1000 is derived from laboratory strain 8325-4 with a defect in *rsbU* restored to wild type (36). *L. lactis* strain MG1363 was employed as a surrogate host for constitutive expression of *S. aureus* surface proteins ClfA and ClfB from the erythromycin resistance conferring plasmid pKS80 (19). *S. aureus* Newman (18) and the *S. aureus* strain 8325-4 SH1000 (36) were used to assess fibronectin binding. *L. lactis* MG1363 was used for heterologous expression of ClfA and ClfB (19).

(ii) Bacterial growth and preparation. *Staphylococcus aureus* Newman and SH1000 were grown in brain heart infusion (BHI) broth (Oxoid, UK), at 37°C with orbital shaking at 220 rpm. *L. lactis* MG1363 wild type and *L. lactis* expressing ClfA and ClfB were grown as static cultures at 30°C in M17 broth (Oxoid, UK) supplemented with 0.5% glucose and 5 μg/mL erythromycin.

Bacterial growth curves were used to ascertain when cultures had reached exponential phase. Single colonies were used to generate starter cultures overnight, which were then used to inoculate larger volumes of broth. Samples were taken every 30 min and absorbance measured at 600 nm using the Ultrospec III spectrophotometer (Pharmacia Biotech UK), to determine when the cultures had reached exponential phase. A single colony was used to inoculate overnight broth cultures used to prepare bacteria for experiments that required stationary phase bacteria.

Bacterial cultures were centrifuged at 5,000 × *g* at room temperature for 10 min. The broth was discarded and the pellets washed in PBS and centrifuged again at 5,000 × *g* for a further 10 min. The resulting pellets were resuspended in PBS to the relevant optical density (OD), measured using the Ultrospec III spectrophotometer (Pharmacia Biotech, UK), at 600 nm. OD₆₀₀ 1.6 was used for platelet aggregations, and OD₆₀₀ of 1.0 was

used for adhesion assays. The optical density, (OD_{600}) of 1.6 corresponds to approximately 7×10^9 cells, and OD_{600} of 1.0 corresponds to approximately 3×10^9 cells (determined using CFU counts).

(iii) Bacterial adhesion assay. Adhesion assays were carried out according to Hartford et al. (37). Briefly, plates were coated with 10 μ g/mL fibrinogen (Calbiochem, Darmstadt, Germany) or 20 μ g/mL fibronectin (Sigma-Aldrich, Ireland) for 2 h at 37°C or for 16 h at 4°C. Plates were blocked with 1% BSA at 37°C for 1 h and washed 3 times in PBS. Washed bacteria were incubated at 37°C for 2 h. Adherent bacteria were washed three times in PBS and fixed in 5–9% formaldehyde at room temperature for 30 min. Wells were washed three times in PBS and stained using 5% crystal violet for 20 min. Wells were washed three times in PBS, and the crystal violet solubilized using 5% acetic acid. Plates were read at 570 nm on a Wallac Victor₂, (Shelton, CT, USA). The minimum adhesion inhibitory concentration (MAIC) was determined as the concentration inhibiting greater than 90% bacterial adhesion.

(iv) Compound screening. Compounds were added to the bacterial suspension prior to addition to the wells. In each experiment, vehicle controls were prepared using the same volume of vehicle for the matching test compound.

(v) Antimicrobial assay. *S. aureus* was grown overnight in BHI broth at 37°C in shaking incubator. Wells were inoculated with 10 μ L of overnight culture into 90 μ L of broth containing the test compounds or controls. A growth control containing no agents was used (positive control), a sterility control of broth alone was included, and vehicle controls were included for each test compound. Plates were incubated overnight at 37°C and absorbance measured at 570 nm the following day using a Wallac Victor₂, (Shelton, CT, USA).

(vi) ELISA. Recombinant GST-tagged L2v lorricin (120 nM) was coated onto a microtiter plate (Nunc Maxisorb) in sodium carbonate buffer (15 mM Na_2CO_3 , 35 mM $NaHCO_3$, pH 9.6) for 16 h at 4°C. Wells were washed three times with PBS and were incubated for 2 h at 37°C with 5% (wt/vol) skimmed milk proteins in PBS to block nonspecific binding. Wells were washed again, and recombinant His-tagged ClfB alone (5 μ M), with allantodapson (100 μ M) or with DMSO was added to the coated wells. Plates were incubated for 1 h at room temperature with shaking. Bound ClfB was detected with peroxidase-conjugated anti-His monoclonal antibody in 1% (wt/vol) skimmed milk proteins in PBS. After washing, 100 μ L of chromogenic substrate solution (1 mg/mL tetramethylbenzidine and 0.006% H_2O_2 in 0.05 M phosphate citrate buffer pH 5.0) was added, and plates were developed for 10 min in the dark. The reaction was stopped by the addition of 2 M H_2SO_4 (50 μ L/well), and the A_{450} was measured in a plate reader (Labsystems).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 1.5 MB.

ACKNOWLEDGMENTS

Research was supported by funding from the Science Foundation Ireland (SFI-TIDA 16/TIDA/3924), British Skin Foundation Research Project Grant (7013s), the Saudi Arabian Cultural Bureau in Ireland, and the Kuwaiti Ministry of Higher Education. We thank the National Cancer Institute (Bethesda, USA) for the kind gift of allantodapson for use in this study. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

- Morrisette T, Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Rybak MJ. 2020. The evolving reduction of vancomycin and daptomycin susceptibility in MRSA—salvaging the gold standards with combination therapy. *Antibiotics* 9:762. <https://doi.org/10.3390/antibiotics9110762>.
- Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G, Day NP. 2002. Virulent combinations of adhesin and toxin genes in natural populations of *Staphylococcus aureus*. *Infect Immun* 70:4987–4996. <https://doi.org/10.1128/IAI.70.9.4987-4996.2002>.
- Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D, Foster TJ. 2005. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol* 57:804–818. <https://doi.org/10.1111/j.1365-2958.2005.04731.x>.
- Miajlovic H, Loughman A, Brennan M, Cox D, Foster TJ. 2007. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by *Staphylococcus aureus* clumping factor B. *Infect Immun* 75:3335–3343. <https://doi.org/10.1128/IAI.01993-06>.
- McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, Foster T, Hook M. 1997. Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. *Eur J Biochem* 247:416–424. <https://doi.org/10.1111/j.1432-1033.1997.00416.x>.
- Ni Eidhin D, Perkins S, Francois P, Vaudaux P, Hook M, Foster TJ. 1998. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of *Staphylococcus aureus*. *Mol Microbiol* 30:245–257. <https://doi.org/10.1046/j.1365-2958.1998.01050.x>.
- Walsh EJ, Miajlovic H, Gorkun OV, Foster TJ. 2008. Identification of the *Staphylococcus aureus* MSCRAMM clumping factor B (ClfB) binding site in the α C-domain of human fibrinogen. *Microbiology (Reading)* 154:550–558. <https://doi.org/10.1099/mic.0.2007/010868-0>.
- O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. 2002. *Staphylococcus aureus* clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. *Cell Microbiol* 4: 759–770. <https://doi.org/10.1046/j.1462-5822.2002.00231.x>.
- Walsh EJ, O'Brien LM, Liang X, Hook M, Foster TJ. 2004. Clumping factor B, a fibrinogen-binding MSCRAMM (microbial surface components recognizing adhesive matrix molecules) adhesin of *Staphylococcus aureus*, also binds to the tail region of type I cytokeratin 10. *J Biol Chem* 279:50691–50699. <https://doi.org/10.1074/jbc.M408713200>.
- Haim M, Trost A, Maier CJ, Achatz G, Feichtner S, Hintner H, Bauer JW, Onder K. 2010. Cytokeratin 8 interacts with clumping factor B: a new possible virulence factor target. *Microbiology (Reading)* 156:3710–3721. <https://doi.org/10.1099/mic.0.034413-0>.
- Mulcahy ME, Geoghegan JA, Monk IR, O'Keefe KM, Walsh EJ, Foster TJ, McLoughlin RM. 2012. Nasal colonisation by *Staphylococcus aureus* depends upon clumping factor B binding to the squamous epithelial cell envelope

- protein loricrin. *PLoS Pathog* 8:e1003092. <https://doi.org/10.1371/journal.ppat.1003092>.
12. Vitry P, Valotteau C, Feuillie C, Bernard S, Alsteens D, Geoghegan JA, Dufrene YF. 2017. Force-induced strengthening of the interaction between *Staphylococcus aureus* clumping factor B and loricrin. *mBio* 8:e01748-17. <https://doi.org/10.1128/mBio.01748-17>.
 13. Ganesh VK, Rivera JJ, Smeds E, Ko YP, Bowden MG, Wann ER, Gurusiddappa S, Fitzgerald JR, Hook M. 2008. A structural model of the *Staphylococcus aureus* ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. *PLoS Pathog* 4:e1000226. <https://doi.org/10.1371/journal.ppat.1000226>.
 14. Ganesh VK, Barbu EM, Deivanayagam CC, Le B, Anderson AS, Matsuka YV, Lin SL, Foster TJ, Narayana SV, Hook M. 2011. Structural and biochemical characterization of *Staphylococcus aureus* clumping factor B/ligand interactions. *J Biol Chem* 286:25963–25972. <https://doi.org/10.1074/jbc.M110.217414>.
 15. Xiang H, Feng Y, Wang J, Liu B, Chen Y, Liu L, Deng X, Yang M. 2012. Crystal structures reveal the multi-ligand binding mechanism of *Staphylococcus aureus* ClfB. *PLoS Pathog* 8:e1002751. <https://doi.org/10.1371/journal.ppat.1002751>.
 16. Irwin JJ, Shoichet BK. 2005. ZINC—a free database of commercially available compounds for virtual screening. *J Chem Inf Model* 45:177–182. <https://doi.org/10.1021/ci049714>.
 17. Wang FD, Wu PF, Chen SJ. 2019. Distribution of virulence genes in bacteremic methicillin-resistant *Staphylococcus aureus* isolates from various sources. *J Microbiol Immunol Infect* 52:426–432. <https://doi.org/10.1016/j.jmii.2019.01.001>.
 18. Duthie ES, Lorenz LL. 1952. *Staphylococcal coagulase*: mode of action and antigenicity. *J Gen Microbiol* 6:95–107. <https://doi.org/10.1099/00221287-6-1-2-95>.
 19. O'Brien L, Kerrigan SW, Kaw G, Hogan M, Penades J, Litt D, Fitzgerald DJ, Foster TJ, Cox D. 2002. Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Mol Microbiol* 44:1033–1044. <https://doi.org/10.1046/j.1365-2958.2002.02935.x>.
 20. Evan AP, Mong SA, Connors BA, Aronoff GR, Luft FC. 1984. The effect of alloxan, and alloxan-induced diabetes on the kidney. *Anat Rec* 208:33–47. <https://doi.org/10.1002/ar.1092080105>.
 21. Ruben JA, Yardumian K. 1946. Diabetes produced by feeding alloxan to cats. *Science* 103:220. <https://doi.org/10.1126/science.103.2669.220>.
 22. Oliveira L, Langoni H, Hulland C, Ruegg PL. 2012. Minimum inhibitory concentrations of *Staphylococcus aureus* recovered from clinical and sub-clinical cases of bovine mastitis. *J Dairy Sci* 95:1913–1920. <https://doi.org/10.3168/jds.2011-4938>.
 23. Wang H, Wang M, Xu X, Gao P, Xu Z, Zhang Q, Li H, Yan A, Kao RY, Sun H. 2021. Multi-target mode of action of silver against *Staphylococcus aureus* endows it with capability to combat antibiotic resistance. *Nat Commun* 12:3331. <https://doi.org/10.1038/s41467-021-23659-y>.
 24. Zhanel GG, Del Rosso JQ. 2016. Activity of dapson versus community and hospital pathogens from the CANWARD study. *J Clin Aesthet Dermatol* 9:42–47.
 25. Rodriguez F, Rozas I, Ortega JE, Meana JJ, Callado LF. 2007. Guanidine and 2-aminoimidazoline aromatic derivatives as α 2-adrenoceptor antagonists, 1: toward new antidepressants with heteroatomic linkers. *J Med Chem* 50:4516–4527. <https://doi.org/10.1021/jm070229q>.
 26. Previtali V, Trujillo C, Amet R, Zisterer DM, Rozas I. 2018. Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents. *Medchemcomm* 9:735–743. <https://doi.org/10.1039/c8md00089a>.
 27. Hartford OM, Wann ER, Hook M, Foster TJ. 2001. Identification of residues in the *Staphylococcus aureus* fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding. *J Biol Chem* 276:2466–2473. <https://doi.org/10.1074/jbc.M007979200>.
 28. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, Hook M, Narayana SV. 2002. A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. *EMBO J* 21:6660–6672. <https://doi.org/10.1093/emboj/cdf619>.
 29. Spannhoff A, Heinke R, Bauer I, Trojer P, Metzger E, Gust R, Schule R, Brosch G, Sippl W, Jung M. 2007. Target-based approach to inhibitors of histone arginine methyltransferases. *J Med Chem* 50:2319–2325. <https://doi.org/10.1021/jm061250e>.
 30. Towell AM, Feuillie C, Vitry P, Da Costa TM, Mathelie-Guinlet M, Kezic S, Fleury OM, McAleer MA, Dufrene YF, Irvine AD, Geoghegan JA. 2021. *Staphylococcus aureus* binds to the N-terminal region of corneodesmosin to adhere to the stratum corneum in atopic dermatitis. *Proc Natl Acad Sci U S A* 118:e201444118. <https://doi.org/10.1073/pnas.2014441118>.
 31. Fleury OM, McAleer MA, Feuillie C, Formosa-Dague C, Sanssevere E, Bennett DE, Towell AM, McLean WHI, Kezic S, Robinson DA, Fallon PG, Foster TJ, Dufrene YF, Irvine AD, Geoghegan JA. 2017. Clumping factor B promotes adherence of *Staphylococcus aureus* to corneocytes in atopic dermatitis. *Infect Immun* 85:e00994-16. <https://doi.org/10.1128/IAI.00994-16>.
 32. Ganesh VK, Liang X, Geoghegan JA, Cohen ALV, Venugopalan N, Foster TJ, Hook M. 2016. Lessons from the crystal structure of the *S. aureus* surface protein clumping factor A in complex with tefibazumab, an inhibiting monoclonal antibody. *EBioMedicine* 13:328–338. <https://doi.org/10.1016/j.ebiom.2016.09.027>.
 33. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of *Staphylococcus aureus* protein based vaccines: monitoring antigenic diversity. *Hum Vaccin* 7(Suppl 1):51–59. <https://doi.org/10.4161/hv.7.0.14562>.
 34. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. *Nucleic Acids Res* 28:235–242. <https://doi.org/10.1093/nar/28.1.235>.
 35. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM. 2009. Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. *FASEB J* 23:3393–3404. <https://doi.org/10.1096/fj.09-135467>.
 36. Horsburgh MJ, Aish JL, White IJ, Shaw L, Lithgow JK, Foster SJ. 2002. σ^B modulates virulence determinant expression and stress resistance: characterization of a functional *rsbU* strain derived from *Staphylococcus aureus* 8325-4. *J Bacteriol* 184:5457–5467. <https://doi.org/10.1128/JB.184.19.5457-5467.2002>.
 37. Hartford O, Francois P, Vaudaux P, Foster TJ. 1997. The dipeptide repeat region of the fibrinogen-binding protein (clumping factor) is required for functional expression of the fibrinogen-binding domain on the *Staphylococcus aureus* cell surface. *Mol Microbiol* 25:1065–1076. <https://doi.org/10.1046/j.1365-2958.1997.5291896.x>.
 38. Gasson MJ. 1983. Plasmid complements of *Streptococcus lactis* NCD0 712 and other lactic streptococci after protoplast-induced curing. *J Bacteriol* 154:1–9. <https://doi.org/10.1128/jb.154.1.1-9.1983>.